PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Experimental Medicine and Immunotherapeutics, University of Cambridge, Level 6, Addenbrooke\'s Centre for Clinical Investigation, Addenbrooke\'s Hospital, Box 110, Cambridge, CB2 0QQ, UK.\', \'Wellcome Trust-MRC Institute of Metabolic Science, Metabolic Research Laboratories, Addenbrooke\'s Biomedical Campus, Cambridge, UK.\', \'Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.\', \'Department of Pathology, Royal Papworth Hospital NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.\', \'Experimental Medicine and Immunotherapeutics, University of Cambridge, Level 6, Addenbrooke\'s Centre for Clinical Investigation, Addenbrooke\'s Hospital, Box 110, Cambridge, CB2 0QQ, UK. apd10@medschl.cam.ac.uk.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41598-021-03731-9
?:doi
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 34934117
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
is ?:relation_isRelatedTo_publication of
?:title
  • Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all